Description

Simple

A medication used to treat inflammation, immune reactions, hormone conditions, and abnormal cell growth.

Clinical

A corticosteroid used to treat inflammation or immune-mediated reactions and to treat endocrine or neoplastic diseases.

Overview

A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver.

Pharmacology

Indication

For the treatment of drug-induced allergic reactions, perennial or seasonal allergic rhinitis, serum sickness, giant cell arteritis acute rheumatic or nonrheumatic carditis, systemic dermatomyositis, systemic lupus erythematosus, atopic dermatitis, contact dermatitis, exfoliative dermatitis, bullous... Read more

Pharmacodynamic

Prednisone, the most commonly-prescribed corticosteroid, is used to treat allograft rejection, asthma, systemic lupus erythematosus, and many other inflammatory states. Prednisone has some mineralocorticoid activity and thus may affect ion exchange in the kidney.

Mechanism of action

Prednisone is a glucocorticoid receptor agonist. It is first metabolized in the liver to its active form, prednisolone. Prednisolone crosses cell membranes and binds with high affinity to specific cytoplasmic receptors. The result includes inhibition of leukocyte infiltration at the site of inflamma... Read more

Absorption

Readily absorbed from the gastrointestinal tract. Rayos, the delayed-release formulation, has a 4-hour release time. To compare, the delayed-release formulation has a Tmax of 6.0 - 6.5 hours in healthy male subjects, whereas the immediate-release formulation has a Tmax of 2.0 hours. The rate of abso... Read more

Protein binding

Extensively bound to plasma proteins.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Half life of both the immediate- and delayed- release formulation is 2 to 3 hours.

Route of elimination

Excreted in the urine as sulfate and glucuronide conjugates.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

  • Regions: US
  • Patient Conditions:
      • Name: Systemic fungal infection
      • Drugbank Id: DBCOND0100019

Food Interactions

  • Avoid alcohol.
  • Avoid taking with grapefruit juice.
  • Take with food to reduce irritation.
  • When Rayos, the delayed-release tablet, is taken without food, Cmax and bioavailability were lower compared to the fed state.

Interactions

Type in a drug name to check for interaction with Prednisone
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
(R)-warfarin
The metabolism of (R)-warfarin can be increased when combined with Prednisone.
(S)-Warfarin
The metabolism of (S)-Warfarin can be increased when combined with Prednisone.
1-Testosterone
The risk or severity of edema formation can be increased when 1-Testosterone is combined with Prednisone.
1,10-Phenanthroline
The therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Prednisone.
16-Bromoepiandrosterone
The risk or severity of edema formation can be increased when 16-Bromoepiandrosterone is combined with Prednisone.
19-norandrostenedione
The risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Prednisone.
1alpha-Hydroxyvitamin D5
The therapeutic efficacy of 1alpha-Hydroxyvitamin D5 can be decreased when used in combination with Prednisone.
1alpha,24S-Dihydroxyvitamin D2
The therapeutic efficacy of 1alpha,24S-Dihydroxyvitamin D2 can be decreased when used in combination with Prednisone.
2-Methoxyethanol
The risk or severity of adverse effects can be increased when Prednisone is combined with 2-Methoxyethanol.
2,4-thiazolidinedione
The risk or severity of hyperglycemia can be increased when Prednisone is combined with 2,4-thiazolidinedione.
4-hydroxycoumarin
Prednisone may increase the anticoagulant activities of 4-hydroxycoumarin.
4-Hydroxytestosterone
The risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Prednisone.
5-androstenedione
The risk or severity of edema formation can be increased when 5-androstenedione is combined with Prednisone.
9-(N-methyl-L-isoleucine)-cyclosporin A
The risk or severity of adverse effects can be increased when Prednisone is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
9-aminocamptothecin
The metabolism of 9-aminocamptothecin can be increased when combined with Prednisone.
Abacavir
Prednisone may decrease the excretion rate of Abacavir which could result in a higher serum level.
Abatacept
The risk or severity of adverse effects can be increased when Prednisone is combined with Abatacept.
Abediterol
The risk or severity of hypokalemia can be increased when Prednisone is combined with Abediterol.
Abemaciclib
The serum concentration of Abemaciclib can be increased when it is combined with Prednisone.
Abetimus
The risk or severity of adverse effects can be increased when Prednisone is combined with Abetimus.